International Journal of
Reproductive Biomedicine
Sat, Apr 27, 2024
[Archive]
Volume 11, Issue 11 (12-2013)
IJRM 2013, 11(11): 883-0 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Swellam M, Khaial A, Mosa T, El-Baz H, Said M. Anti-mullerian and androgens hormones in women with polycystic ovary syndrome undergoing IVF/ICSI. IJRM 2013; 11 (11) :883-0
URL: http://ijrm.ir/article-1-367-en.html
URL: http://ijrm.ir/article-1-367-en.html
1- Department of Biochemistry, Genetic Engineering and Biotechnology Research Division, National Research Center, Dokki, Giza, Egypt
2- Department of Biochemistry, Genetic Engineering and Biotechnology Research Division, National Research Center, Dokki, Giza, Egypt , dr_tamermosa@hotmail.com
3- Department of Obstetrics and Gynecology, Ain-Shams University, Cairo, Egypt
2- Department of Biochemistry, Genetic Engineering and Biotechnology Research Division, National Research Center, Dokki, Giza, Egypt , dr_tamermosa@hotmail.com
3- Department of Obstetrics and Gynecology, Ain-Shams University, Cairo, Egypt
Abstract: (2845 Views)
Background: Despite its frequency, the polycystic ovary syndrome (PCOS) is still a difficult diagnosis in endocrinology, gynecology, and reproductive medicine. The Rotterdam consensus conference proposed to include the ultrasonographic follicle count as a new diagnostic criterion. Unfortunately, its assessment does not offer sufficient reliability worldwide.
Objective: To explore the possible roles of altered circulating androgens and anti-mullerian hormone among PCOS women regarding their body mass index and their outcomes after IVF.
Materials and Methods: In this cross sectional study, 195 women with PCO were included, they were divided according to their body mass index (BMI <27 kg/m2) as obese PCOS (n=91) and overweight PCOS (BMI ≥27 kg/m2) (n=104). Serum levels of androgens (dehydroepiandrosterone sulfate [DHEAS], testosterone and androstenedione [A4]), and anti-mullerian hormone (AMH) were assessed and compared with the endocrine profile and cycles outcomes.
Results: AMH, A4, FSH, and TSH concentrations were significantly higher in obese than in overweight women (p˂0.001). Contrary, LH: FSH ratio values, E2, PRL and DAHE-S levels were significantly lower in obese than in overweight women (p˂0.0001). Total oocyte retrieved, mature and fertilized oocyte were significantly higher in obese than in overweight women. Among pregnant obese PCOS women both AMH and A4 were significantly increased and DAHE-S was significantly decreased compared to pregnant overweight PCOS women.
Conclusion: Obese PCOS women have a higher chance of getting pregnant over those categorized as overweight PCOS. Also, androgens and AMH levels recommended to be considered in IVF attributes among obese and overweight PCOS women.
Objective: To explore the possible roles of altered circulating androgens and anti-mullerian hormone among PCOS women regarding their body mass index and their outcomes after IVF.
Materials and Methods: In this cross sectional study, 195 women with PCO were included, they were divided according to their body mass index (BMI <27 kg/m2) as obese PCOS (n=91) and overweight PCOS (BMI ≥27 kg/m2) (n=104). Serum levels of androgens (dehydroepiandrosterone sulfate [DHEAS], testosterone and androstenedione [A4]), and anti-mullerian hormone (AMH) were assessed and compared with the endocrine profile and cycles outcomes.
Results: AMH, A4, FSH, and TSH concentrations were significantly higher in obese than in overweight women (p˂0.001). Contrary, LH: FSH ratio values, E2, PRL and DAHE-S levels were significantly lower in obese than in overweight women (p˂0.0001). Total oocyte retrieved, mature and fertilized oocyte were significantly higher in obese than in overweight women. Among pregnant obese PCOS women both AMH and A4 were significantly increased and DAHE-S was significantly decreased compared to pregnant overweight PCOS women.
Conclusion: Obese PCOS women have a higher chance of getting pregnant over those categorized as overweight PCOS. Also, androgens and AMH levels recommended to be considered in IVF attributes among obese and overweight PCOS women.
Type of Study: Original Article |
References
1. Panidis D, Farmakiotis D, Rousso D, Katsikis I, Kourtis A, Diamanti-Kandarakis E. Serum luteinizing hormone levels are markedly increased and significantly correlated with D4-androstenedione levels in lean women with polycystic ovary syndrome. Fertil Steril 2005; 84: 538-540. [DOI:10.1016/j.fertnstert.2005.02.017]
2. Xiaomiao Zhao X, He Z, Mo Y, Chen X, Chen Y, Yang D. "Determining the normal cut-off levels for hyperandrogenemia in Chinese women of reproductive age". Eur J Obstet Gynecol Reprod Biol 2011; 154: 187-191. [DOI:10.1016/j.ejogrb.2010.10.021]
3. Durlinger AL, Gruijters MJ, Kramer P, Karels B, Ingraham HA, Nachtigal MW, et al. Anti-Mullerian hormone inhibits initiation of primordial follicle growth in the mouse ovary. Endocrinology 2002; 143: 1076-1084. [DOI:10.1210/endo.143.3.8691]
4. Das M, Gillott D, Saridogan E, Djahanbakhch O. Anti-Mullerian hormone is increased in follicular fluid from unstimulated ovaries in women with polycystic ovary syndrome. Hum Reprod 2008; 23: 2122-2126. [DOI:10.1093/humrep/den185]
5. Marca A, Malmusi S, Giulini S, Tamaro LF, Orvieto R, Levratti P, et al. Anti-Mullerian hormone plasma levels in spontaneous menstrual cycle and during treatment with FSH to induce ovulation. Hum Reprod 2004; 19: 2738-2741. [DOI:10.1093/humrep/deh508]
6. Laven JS, Mulders AG, Visser JA, Themmen AP, De Jong FH, Fauser BC. Anti-mullerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metab 2004; 89: 318-323. [DOI:10.1210/jc.2003-030932]
7. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004a; 19: 41-47. [DOI:10.1093/humrep/deh098]
8. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Fertil Steril 2004b; 81: 19-25. [DOI:10.1016/j.fertnstert.2003.10.004]
9. Marshall K. Polycystic Ovary Syndrome: Clinical Considerations. Altern Med Rev 2001; 6: 272-292.
10. Panidis D, Katsikis I, Karkanaki A, Piouka A, Armeni K, Georgopoulos NA. Serum Anti-Müllerian hormone (AMH) levels are differentially modulated by both serum gonadotropins and not only by serum Follicle Stimulating Hormone (FSH) levels. Med Hypothes 2011; 77: 649-653. [DOI:10.1016/j.mehy.2011.07.005]
11. Chanukvadze D, Kristesashvili J, Kvashilava N. Correlation of biochemical markers and clinical signs of hyperandrogenism in women with polycystic ovary syndrome (PCOS) and women with non-classic congenital adrenal hyperplasia (NCAH). Iran J Reprod Med 2012; 10: 307-314.
12. Marx TL, Mehta ME. Polycystic ovary syndrome: Pathogenesis and treatment over the short and long term. Clev Clin J Med 2003; 70: 31-45. [DOI:10.3949/ccjm.70.1.31]
13. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HE, Futterweit W, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 2009; 91: 456- 488. [DOI:10.1016/j.fertnstert.2008.06.035]
14. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. Position statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 2006; 91: 4237-4245. [DOI:10.1210/jc.2006-0178]
15. Carlsen SM, Vanky E, Fleming R. Anti-Mullerian hormone concentrations in androgen-suppressed women with polycystic ovary syndrome. Hum Reprod 2009; 24: 1732-1738. [DOI:10.1093/humrep/dep074]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
